Cam Bioceramics announced sale to SHS Capital

Cam Bioceramics announced sale to SHS Capital

Cam Bioceramics announced the sale of a majority stake in the company to German specialist healthcare investor SHS Capital, ING Corporate Investments and several co-investors to support and accelerate its future growth

Cam Bioceramics announced sale to SHS Capital

Axeco Corporate Finance is pleased to have advised the management and shareholders of CAM Bioceramics

Together with ING Corporate Investments and several Co-Investors, the German specialist healthcare investor SHS Capital acquires a majority stake in Cam Bioceramics, a leading global manufacturer of innovative calcium phosphate solutions for Medtech and LifeScience applications based in Leiden, the Netherlands, while current owners remain significant shareholders. This investment is the third transaction for the newly launched SHS VI fund and one of the largest investments in SHS’ history.


About Cam Bioceramics

CAM Bioceramics B.V. was the first company in 1980’s to provide innovative HA plasma-sprayed coatings on orthopedic implants. Since then, our pioneering work has led to the worldwide adoption of plasma- sprayed hydroxyapatite coatings. HA Coating was the first step in the formation of the fully-fledged organization CAM Bioceramics is today. As a dedicated contract development and manufacturing organization, CAM Bioceramics has set up robust processes to develop or co-develop and manufacture an extensive portfolio of orthobiologic calcium phosphates. CAM Bioceramics is able to research, develop, engineer and manufacture orthobiologic calcium phosphate powders, granules, blocks and excipients for drug delivery. CAM Bioceramics delivers these components to the industry leaders in the orthopedic, dental and aesthetic sectors. Our entire team at CAM Bioceramics is committed to meeting and exceeding customers’ expectations. Our class-7 cleanrooms enable our experienced staff of engineering, production, and quality assurance & control specialists to produce to robust ISO 13485:2016 and ANVISA standards while maintaining a competitive pricing strategy. Our offices and in-house production facilities are located in Leiden Bio Science Park, a leading life sciences cluster. Situated close to Amsterdam Schiphol Airport and other major European and global logistics hubs, we provide a highly reliable service to customers all over the world.


About SHS Capital

SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The German investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 40 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 250 million.


About ING Corporate Investments

ING Corporate Investments, a 100% subsidiary of ING Bank N.V., offers tailored risk bearing capital solutions beyond traditional bank financing ranging from subordinated debt to ordinary equity. ING Corporate Investments supports companies in achieving strategic ambitions, by providing growth capital and access to the ING global institution and its local expertise. ING Corporate Investments has invested over €1.5 billion in the past 10 years.

Geen reactie's

Sorry, het is niet mogelijk om te reageren.